The buyback follows a separate $15 billion stock repurchase Allergan announced last year.
“We continue to believe that Allergan stock is substantially undervalued, and the share price today presents a unique investment opportunity for the company,” said CEO Brent Saunders. “Our financial strength and cash flow, strong portfolio of products and diversified pipeline allow us to balance return of capital to shareholders through a flexible share repurchase program.”
Allergan also announced the retirement of CFO Tessa Hilado Monday. The drugmaker declined Reuter’s request for comment on the departure, but said it has already initiated the search for a new CFO.
More articles on supply chain:
Why pharmaceutical products in the US don’t include braille labeling
Abbott earns FDA approval for MRI-compatible defibrillator
6 drug, devicemakers in the headlines
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.